PLG and prostate carcinoma: A similar pattern of ECM degradation characterizes the invasive prostate cancer cell-specific activity of uPA, the proteinase simultaneously involved in the activation of latent MMPs and conversion of plasminogen into the functional, matrix-degrading enzyme plasmin (Sheng, 2001[118]; Arya et al., 2006[15]).